AcelRx Pharmaceuticals (ACRX) News Today → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free ACRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineTalphera’s Strategic Rebrand and Niyad’s Market Potential Bolster Buy Ratingmarkets.businessinsider.com - January 11 at 3:37 PMAcelRx announces rebranding with name change to Talpheramsn.com - January 9 at 10:31 AMAcelRx Announces Rebranding With Name Change to Talphera, Inc.finance.yahoo.com - January 9 at 10:31 AMAcelRx Pharmaceuticals Stock (NASDAQ:ACRX) Dividends: History, Yield and Datesbenzinga.com - December 22 at 6:12 PMAcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United Statesfinance.yahoo.com - December 12 at 9:00 AMAcelRx Pharmaceuticals files for $150M mixed shelfmsn.com - November 22 at 6:03 PMAcelRx Pharmaceuticals, Inc.: AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - November 9 at 10:48 AMAcelRx Pharmaceuticals Q3 2023 Earnings Previewmsn.com - November 7 at 10:18 PMAcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Studyfinance.yahoo.com - November 7 at 5:17 PMAcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023finance.yahoo.com - October 26 at 7:53 PMAcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Studyfinance.yahoo.com - October 3 at 9:51 AMAcelRx CEO buys 10,000 sharesmsn.com - September 12 at 5:37 PMInsider Buying: CEO Vincent Angotti Acquires 10,000 Shares of AcelRx Pharmaceuticals Incfinance.yahoo.com - September 12 at 5:37 PMWhat Makes AcelRx Pharmaceuticals (ACRX) a New Buy Stockfinance.yahoo.com - August 22 at 11:54 PMPositive Report for Acelrx (ACRX) from H.C. Wainwrightmarkets.businessinsider.com - August 18 at 7:06 AMAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q2 2023 Earnings Call Transcriptfinance.yahoo.com - August 13 at 6:53 AMAcelRx Pharmaceuticals, Inc.: AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - August 12 at 12:51 AMQ2 2023 AcelRx Pharmaceuticals Inc Earnings Callfinance.yahoo.com - August 11 at 7:50 PMAcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 11 at 3:05 AMAcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimatesfinance.yahoo.com - August 11 at 3:05 AMAcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023finance.yahoo.com - July 28 at 10:16 AMAcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - July 21 at 8:53 AMAcelRx Pharmaceuticals launches ~$10M private placement of sharesseekingalpha.com - July 18 at 9:51 AMAcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - July 18 at 9:51 AMACRX - AcelRx Pharmaceuticals, Inc.finance.yahoo.com - June 17 at 8:16 PMAcelRx Pharmaceuticals (NASDAQ: ACRX)fool.com - June 16 at 5:46 PMAcelRx Pharmaceuticals, Inc.: AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - May 13 at 6:18 AMRecap: AcelRx Pharmaceuticals Q1 Earningsmsn.com - May 11 at 10:29 PMAcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1finance.yahoo.com - May 10 at 9:28 PMAcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 10 at 4:27 PMEarnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Declinefinance.yahoo.com - May 4 at 1:29 PMAcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Releasemsn.com - May 3 at 12:27 PMAcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023finance.yahoo.com - April 27 at 7:24 PMAcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticalsfinance.yahoo.com - April 5 at 9:38 AMAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q4 2022 Earnings Call Transcriptfinance.yahoo.com - April 4 at 2:20 PMAcelRx Pharmaceuticals, Inc.: AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 31 at 10:33 AMAcelrx (ACRX) Receives a Hold from H.C. Wainwrightmarkets.businessinsider.com - March 31 at 10:33 AMAcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - March 30 at 6:44 PMEarnings Outlook For AcelRx Pharmaceuticalsmsn.com - March 29 at 5:42 PMAcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023finance.yahoo.com - March 21 at 5:29 PMAcelRx Pharmaceuticals Shares Rise Premarket on Dsuvia Sale >ACRXmarketwatch.com - March 14 at 6:55 PMAcelRx adds 16% on plans to divest pain therapymsn.com - March 14 at 6:55 PMAcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticalsfinance.yahoo.com - March 14 at 6:55 PMHere's Why AcelRx Pharmaceuticals (ACRX) Stock Gained Todaythestreet.com - February 24 at 7:56 AMAcelrx Pharmaceuticalsforbes.com - January 18 at 11:46 PMAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call Transcriptfinance.yahoo.com - December 29 at 8:24 AMAcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stockfinance.yahoo.com - December 27 at 1:32 PMThree Healthcare Penny Stocks to Watch In The New Yearmarketbeat.com - December 27 at 1:00 AMThree Healthcare Penny Stocks to Watch In The New Year (ACRX)marketbeat.com - December 26 at 8:37 PMLooking Into AcelRx Pharmaceuticals's Return On Capital Employedbenzinga.com - December 26 at 1:38 PM Get AcelRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now ACRX Media Mentions By Week ACRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRX News Sentiment▼0.000.43▲Average Medical News Sentiment ACRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRX Articles This Week▼00▲ACRX Articles Average Week Get AcelRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Edesa Biotech News Today NeuroBo Pharmaceuticals News Today ABVC BioPharma News Today Aytu BioPharma News Today Kiora Pharmaceuticals News Today NanoViricides News Today Avalo Therapeutics News Today Cocrystal Pharma News Today Tonix Pharmaceuticals News Today Talphera News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRX) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchStock-Picking AI Predicts #1 Stock of 2024AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlaceThe asset beating inflation by 4xColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AcelRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.